USPTO Examiner PERREIRA MELISSA JEAN - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19340137SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORSSeptember 2025January 2026Allow410NoNo
18959449PARTICLE-CONTAINING DROPLET SYSTEMS WITH MONODISPERSE FLUID VOLUMESNovember 2024February 2026Abandon1520YesNo
18927034Stable, concentrated radionuclide complex solutionsOctober 2024February 2025Abandon400NoNo
18927058Stable, concentrated radionuclide complex solutionsOctober 2024August 2025Allow1001YesNo
18927047Stable, concentrated radionuclide complex solutionsOctober 2024May 2025Allow701YesNo
18909354Near-Infrared Dyes And Conjugates For Targeting TumorsOctober 2024September 2025Allow1110NoNo
18819282METHOD OF TREATING CANCERAugust 2024October 2025Abandon1420NoNo
18640891Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640917Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640884Stable, concentrated radionuclide complex solutionsApril 2024September 2024Allow500YesNo
18640907Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18612564LIPIDS AND COMPOSITIONS THEREOFMarch 2024January 2025Allow1010YesNo
18585905IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)February 2024August 2024Allow600NoNo
18410875Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use ThereofJanuary 2024October 2024Abandon910NoNo
18396075MODULAR LIPID COMPOUNDS AND TWO- TO THREE-COMPONENT LIPID NANOPARTICLE COMPOSITIONSDecember 2023November 2025Allow2341YesNo
18572198PREPARATION METHOD OF NANOZYME COMPOSITE-BASED HYBRID HYDROGEL EYE DROPDecember 2023July 2024Allow600NoNo
18526168Method to Improve the Encapsulation Efficiency and Physicochemical Stability of Ginsenosides Rg3 and CK Nano-emulsionDecember 2023July 2024Allow710NoNo
18565770MANUFACTURING OF DIMERIC CONTRAST AGENTSNovember 2023March 2025Allow1630YesNo
18512708RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERSNovember 2023November 2024Allow1221NoNo
18474209FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOFSeptember 2023April 2025Allow1920NoNo
18546989DUAL-TARGETING COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOFAugust 2023March 2024Allow710NoNo
18448609METHOD OF TREATING PROSTATE CANCERAugust 2023June 2025Abandon2340YesNo
18354282IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)July 2023January 2024Allow610YesNo
18257063TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOFJune 2023January 2024Allow710NoNo
18189238MULTI-SIGNAL FLUORESCENT PROBE FOR EARLY DIAGNOSIS OF TUMORS, AND PREPARATION AND USE THEREOFMarch 2023June 2023Allow300NoNo
18111704COMPOSITIONS INCLUDING PAFOLACIANINE FOR THE IDENTIFICATION OF MALIGNANT LESIONSFebruary 2023January 2024Allow1120YesNo
17907973NEAR-INFRARED FLUORESCENT PROBE SPECIFICALLY TARGETING TUMORS AS WELL AS SYNTHESIS METHOD AND USE THEREOFAugust 2022May 2025Allow3320NoNo
17884185Unassisted Robotic Surgery Employing Paramagnetic Halo Metallofullerenes as Minimally Invasive, Precision Scalpels or Micronization Particles through Magnetic Field Manipulation and Targeted Exenteration Patterned by Programmed 3D Imaging Using Needle or Magnetic Energy Access and Microelectronic Semiconducting in Non-stationary Wafer-less Space.August 2022March 2023Allow721YesNo
17795303WHITE, BACTERIA-RESISTANT, BIOCOMPATIBLE, ADHERENT COATING FOR IMPLANTS, SCREWS AND PLATES INTEGRATED IN HARD AND SOFT TISSUE AND PRODUCTION METHODJuly 2022December 2025Abandon4021NoNo
17867030METHODS OF FUNCTIONALIZING NANOPARTICLESJuly 2022January 2025Abandon3050NoNo
17808410CELL CULTURE METHODS AND MEDIA COMPRISING N-ACETYLCYSTEINEJune 2022August 2025Abandon3811YesNo
17718812PSMA-TARGETING COMPOUNDS AND USES THEREOFApril 2022September 2022Allow510NoNo
17767039SYSTEMS AND METHODS OF ISOLATION OF GALLIUM-68April 2022September 2023Abandon1710NoNo
17705007NOVEL COMPOUND HAVING ANTIBACTERIAL FUNCTION AGAINST SUPERBACTERIA AND SELECTIVE DETECTION FUNCTION OF HYPOCHLOROUS ACID, AND COMPOSITION AND SENSOR COMPRISING THE SAMEMarch 2022August 2025Allow4111NoNo
17697401RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASE DIAGNOSIS AND THERAPYMarch 2022February 2023Abandon1111NoNo
17697416SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASESMarch 2022September 2022Allow601NoNo
17633843METHOD AND REAGENTS FOR DETECTING LUCIFERASE ACTIVITYFebruary 2022April 2024Abandon2611NoNo
17528571Chelated PSMA InhibitorsNovember 2021January 2026Abandon5001NoNo
17502372PER-ORAL NEGATIVE CONTRAST AGENT FOR ABDOMINAL IMAGINGOctober 2021November 2025Abandon4910NoNo
17461860RADIOPHARMACEUTICAL AND METHODSAugust 2021August 2022Allow1110YesNo
17408292DELIVERY OF THERAPEUTIC COMPOUNDS WITH IRON OXIDE NANOPARTICLESAugust 2021July 2025Abandon4710NoNo
17398195Lyophilized Compositions Comprising Rhannexin V-128, Process for Their Preparation and Their Use for Preparing Formulations Containing 99MTc-Rhannexin V-128August 2021July 2025Abandon4710NoNo
17397022COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED OF A DIASTEREOISOMERICALLY ENRICHED PCTA AND SYNTHESIS METHODAugust 2021June 2022Allow1020YesNo
17387478COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTSJuly 2021November 2025Abandon5220NoNo
17384998NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATIONJuly 2021November 2025Allow5120YesNo
17423589COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED OF A DIASTEREOISOMERICALLY ENRICHED PCTA AND SYNTHESIS METHODJuly 2021May 2025Abandon4610NoNo
17373987SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOFJuly 2021March 2025Allow4410NoNo
17373950SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOFJuly 2021July 2025Allow4930NoNo
17374984RADIOPHARMACEUTICAL AND METHODSJuly 2021September 2022Allow1420YesNo
17371663NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOFJuly 2021February 2025Abandon4410NoNo
17371587RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGENJuly 2021August 2022Allow1430YesNo
17369104MODIFIED NANODELIVERY SYSTEM AND METHOD FOR ENHANCED IN VIVO MEDICAL AND PRECLINICAL IMAGINGJuly 2021August 2024Allow3700NoNo
17359490COMPOSITIONS AND METHODS FOR DETECTING ACE2 EXPRESSION PROFILESJune 2021December 2023Abandon2910NoNo
17355286SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOFJune 2021November 2024Allow4110NoNo
17331927Methods for Synthesis of Radionuclide ComplexMay 2021February 2025Abandon4420NoNo
17331113PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERYMay 2021April 2024Allow3410NoNo
17318802Organic Anion Transporting Peptide-Based Cancer Imaging and TherapyMay 2021April 2025Allow4720NoNo
17233102MECHANICAL OPENING OF LIPID BILAYERS BY MOLECULAR NANOMACHINESApril 2021September 2022Allow1740YesNo
17209122Stable, concentrated radionuclide complex solutionsMarch 2021November 2023Abandon3210NoNo
17209121Stable, concentrated radionuclide complex solutionsMarch 2021December 2023Abandon3210NoNo
17204196ENHANCED SURGICAL VISUALIZATION OF VIABLE TISSUE AND PEPTIDES THEREFORMarch 2021November 2024Abandon4410NoNo
17199122GADOLINIUM BEARING PCTA-BASED CONTRAST AGENTSMarch 2021March 2024Allow3610YesNo
17185502Compounds and Methods of Making CompoundsFebruary 2021February 2024Abandon3610NoNo
17268954PARTICLE-CONTAINING DROPLET SYSTEMS WITH MONODISPERSE FLUID VOLUMESFebruary 2021September 2025Abandon5530YesNo
17266102PRE-MIXED STRONTIUM SILICATE-BASED BIOLOGICAL HYDRAULIC CEMENTING PASTE COMPOSITION, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFFebruary 2021January 2026Allow6031NoNo
17127754ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USEDecember 2020June 2024Allow4130YesNo
17117424PHYSIOLOGICALLY STABLE FLUOROPHORE AND PERFORMING FLUORESCENCE PROBINGDecember 2020November 2023Allow3520YesNo
17116596BISMUTH-IRON OXIDE CONTRAST AGENTSDecember 2020May 2024Abandon4120NoNo
16973254Pretreatment Method for Fluorescent Image DiagnosisDecember 2020April 2025Allow5230YesNo
16973028COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURYDecember 2020August 2025Allow5640NoNo
17114195SYNTHESIS AND COMPOSITION OF NON-AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORSDecember 2020April 2024Allow4010NoNo
17112075Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen LigandsDecember 2020August 2023Allow3210NoNo
17112497PSMA-TARGETED NIR DYES AND THEIR USESDecember 2020October 2024Abandon4730NoNo
17105308SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORSNovember 2020July 2024Allow4420YesNo
17057284ONE-STEP, FAST, 18F-19F ISOTOPIC EXCHANGE RADIOLABELING OF DIFLUORO-DIOXABORININS AND USE OF SUCH COMPOUNDS IN TREATMENTNovember 2020March 2025Allow5221YesNo
17057506RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPYNovember 2020March 2024Allow4020NoNo
16950107HNQO1-ACTIVATABLE FLUORESCENT PROBE FOR IMAGING CANCER CELLS IN-VITRO AND IN-VIVONovember 2020December 2023Allow3710NoNo
17092587ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USENovember 2020January 2023Allow2610NoNo
17093184SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOFNovember 2020August 2023Allow3320NoNo
17050370NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRASTOctober 2020October 2024Abandon4720NoNo
17074832RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEREOFOctober 2020July 2023Abandon3301NoNo
17047748CYCLOPHANES FOR LIVE-CELL IMAGINGOctober 2020June 2023Allow3210NoNo
17046053TARGETING COMPOUNDS AND METHODS FOR THEIR PRODUCTIONOctober 2020December 2023Allow3830NoNo
17060396DIMERIC CONTRAST AGENTSOctober 2020June 2022Allow2010YesNo
17042772FORMULATIONS AND KITS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGINGSeptember 2020March 2023Allow3030NoNo
17042534USE OF BIS-IMINOBIOTIN COMPOUND FOR DRUG DELIVERY PURPOSESSeptember 2020June 2023Abandon3310NoNo
17041759FORMULATION AND METHOD OF PREPARATIONSeptember 2020August 2025Abandon5950YesNo
17029226PSMA-TARGETED NIR DYES AND THEIR USESSeptember 2020June 2022Allow2110NoNo
17025711CA IX - NIR DYES AND THEIR USESSeptember 2020September 2022Allow2410NoNo
16981843SCAFFOLDSeptember 2020August 2025Abandon5821NoNo
16980252177Lu-DOTA-HYNIC-iPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGENSeptember 2020August 2024Allow4760YesNo
16971671POSITRON EMISSION TOMOGRAPHY IMAGING OF ACTIVATABLE BINDING POLYPEPTIDES AND RELATED COMPOSITIONS THEREOFAugust 2020June 2025Abandon5720NoYes
16970155HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMSAugust 2020June 2023Allow3420NoNo
16990368MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGINGAugust 2020April 2022Allow2010NoNo
16968272OPTICAL IMAGING AGENTS TARGETING INFLAMMATIONAugust 2020October 2025Abandon6050NoNo
16967624COMPOUND FOR INTRAOPERATIVE MOLECULAR BIOIMAGING, METHOD OF MAKING THE SAME, USE THEREOF IN INTRAOPERATIVE MOLECULAR BIOIMAGING AND SURGICAL METHOD COMPRISING INTRAOPERATIVE MOLECULAR BIOIMAGINGAugust 2020June 2024Abandon4720NoNo
16966182BIOINK COMPOSITION FOR DERMIS REGENERATION SHEET, METHOD FOR MANUFACTURING CUSTOMIZED DERMIS REGENERATION SHEET USING SAME, AND CUSTOMIZED DERMIS REGENERATION SHEET MANUFACTURED USING MANUFACTURING METHODJuly 2020February 2024Abandon4211YesNo
16926807TARGETED PHOTOACOUSTIC AGENTS AND USES THEREOFJuly 2020October 2023Abandon3920NoNo
16919562Methods of Using C-Met ModulatorsJuly 2020April 2022Allow2210NoNo
16905718ASSESSMENT OF IRON DEPOSITION POST MYOCARDIAL INFARCTION AS A MARKER OF MYOCARDIAL HEMORRHAGEJune 2020February 2023Allow3210NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PERREIRA, MELISSA JEAN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
46
Examiner Affirmed
35
(76.1%)
Examiner Reversed
11
(23.9%)
Reversal Percentile
37.3%
Lower than average

What This Means

With a 23.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
150
Allowed After Appeal Filing
32
(21.3%)
Not Allowed After Appeal Filing
118
(78.7%)
Filing Benefit Percentile
28.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PERREIRA, MELISSA JEAN - Prosecution Strategy Guide

Executive Summary

Examiner PERREIRA, MELISSA JEAN works in Art Unit 1618 and has examined 963 patent applications in our dataset. With an allowance rate of 48.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner PERREIRA, MELISSA JEAN's allowance rate of 48.6% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PERREIRA, MELISSA JEAN receive 2.58 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PERREIRA, MELISSA JEAN is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +28.2% benefit to allowance rate for applications examined by PERREIRA, MELISSA JEAN. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 13.7% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 34.9% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 54.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 47% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 57.8% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 58.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 74.5% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.7% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.